Giannella, MaddalenaRighi, EldaPascale, RenatoRinaldi, MatteoCaroccia, NatasciaGamberini, ChiaraPalacios-Baena, Zaira RCaponcello, GiuliaMorelli, Maria CristinaTamè, MariarosaBusutti, MarcoComai, GiorgiaPotena, LucianoSalvaterra, ElenaFeltrin, GiuseppeCillo, UmbertoGerosa, GinoCananzi, MaraPiano, SalvatoreBenetti, ElisaBurra, PatriziaLoy, MonicaFurian, LucreziaZaza, GianluigiOnorati, FrancescoCarraro, AmedeoGastaldon, FiorellaNordio, MaurizioKumar-Singh, SamirAbedini, MahsaBoffetta, PaoloRodríguez-Baño, JesúsLazzarotto, TizianaViale, PierluigiTacconelli, EvelinaOn Behalf Of The Orchestra Study Group Workpackage,2023-05-032023-05-032022-05-122076-2607http://hdl.handle.net/10668/21436Previous studies assessing the antibody response (AbR) to mRNA COVID-19 vaccines in solid organ transplant (SOT) recipients are limited by short follow-up, hampering the analysis of AbR kinetics. We present the ORCHESTRA SOT recipients cohort assessed for AbR at first dose (t0), second dose (t1), and within 3 ± 1 month (t2) after the first dose. We analyzed 1062 SOT patients (kidney, 63.7%; liver, 17.4%; heart, 16.7%; and lung, 2.5%) and 5045 health care workers (HCWs). The AbR rates in the SOTs and HCWs were 52.3% and 99.4%. The antibody levels were significantly higher in the HCWs than in the SOTs (penAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/COVID-19antibody responsemRNA vaccinesserologysolid organ transplantationresearch article35630462open access10.3390/microorganisms10051021PMC9147204https://www.mdpi.com/2076-2607/10/5/1021/pdf?version=1652496782https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147204/pdf